Canada’s decision to legalize the recreational use of cannabis has allowed the rise of an emerging investment market. The cannabis public sector has become one of the most followed industries for investors.
As such, the Investing News Network brings investors a collection of stories on the critical transition and its impact on the public markets.
As part of the continued coverage on the effects legalization of recreational cannabis in Canada will have on the public sector, the Investing News Network (INN) talked with Greg Engel, CEO of Organigram Holdings (TSXV:OGI).
Producers in the space with supply deals will finally be able to obtain real numbers on the amount of moved product and the interest from consumers on the newly introduced brands.
Engel gave his prediction on whether or not Health Canada should reconsider the strenuous licensed producer (LP) application process as the market may face a product shortage very soon.
A new market report, co-authored by the the University of Waterloo and the C.D. Howe Institute, shows the supply of cannabis in Canada will reach only 210,000 kilograms during the first year of legalization, well below the the estimated peak demand of 610,000 kilograms.
The cannabis executive also commented on the newfound interest from the US investor into cannabis stocks found on premier exchange and even over the counter ones from the OTC Markets.
This interview has been edited and condensed for clarity and readability. Continue reading for more of what Engel had to say.
Investing News Network: We have seen more cannabis executives publicly support the claim that the market will face a serious shortage following legalization. How quickly do you foresee the stores of the new legal market running out of product?
Greg Engel: My perspective is … it’s going to be different across different parts of the country.
If you think of Atlantic Canada, for example, they got all their stores fully built out and are fully ramped up. I think they were very prescient in signing supply agreements with Organigram, Canopy Growth (NYSE:CGC,TSX:WEED) and a number of other companies to garner supply.
I think the rest of Canada is really staggering behind in terms of not having full retail stores.
Some of the ones that were late looking to get retail supply — for example Saskatchewan — may not have as much product supply early on or in the early parts of the program.
It’s hard to predict what the demand is going to be.
INN: With this projected shortage, do you expect Health Canada to find a way and streamline the LP application process as a way to get more producers online?
GE: What’s causing the delay at this point is really a number of companies not executing in the timelines that they had committed to.
This isn’t about new licensees getting licensed, because the lead time for them to get up and running and be functional and be contributing to the total volume is very significant.
With almost four years of experience in the space, my perspective is there is a very long learning curve to producing cannabis at scale and it’s going to be challenging for new producers to start to meet any semblance of participating from a demand perspective today.
It’s really up to the licensed producers today to continue to increase their production and improve their processes to meet that demand.
Part of what’s causing this is, I remember, companies have had some challenges in execution — whether that’s the build out of their facilities, the yields they are getting, the product they are growing, or some of the delays in packaging.
I think that is the most immediate fix, is for companies that need to focus on that.
I don’t think bringing licensed producers in the midterm is not going to assist in any shape or form for the next 12 to 18 months months anyway.
INN: What will the investor sentiment look like following legalization for these stocks?
GE: We’re seeing a lot of new investors come into Canada, including retail investors as well as some new large funds that have invested in the space. Also, we have seen a dramatic increase in the number of US investors coming into the space.
When we look at the daily volume in the US, we are trading on the OTCQX (OTCQX:OGRMF) and, especially for those companies that are trading on the Nasdaq or New York Stock Exchange, their volumes are up dramatically as US investors are coming in.
Many investors are looking at just the position many Canadian companies are at at this point with legalization.
I think one of the most important things will be for investors to go on the websites, the provinces’, look at who has product for sale, how much product is available there and find out which companies are delivering.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.
Meanwhile, two longstanding cannabis partners ended their relationship.
Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development
Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.
The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.
With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.
DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.